about
Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral thTelmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro.Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohortsTelmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT
P50
description
investigador
@es
researcher
@en
name
Sudeep P Pushpakom
@en
type
label
Sudeep P Pushpakom
@en
prefLabel
Sudeep P Pushpakom
@en
P31
P496
0000-0002-6682-4235